Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

Author(s): M. Florentin, M. S. Elisaf, D. P. Mikhailidis, E. N. Liberopoulos

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 29 , 2009

Become EABM
Become Reviewer


Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations.

Keywords: Bile acid sequestrants, ezetimibe, fibrates, metabolic syndrome, niacin, orlistat, rimonabant, statins

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [3446 - 3462]
Pages: 17
DOI: 10.2174/138161209789105054
Price: $65

Article Metrics

PDF: 3